DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Topp MS, Kufer P, Gokbuget N et al.
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol 2011;
29: 2493-2498
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.